Medication info
Robartan Tablet 10/160 mg

Robartan Tablet 10/160 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletValsartan›160mg / 1 tablet
Manufacturer / importer
Medica Korea Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP) * 3]
Approval status
Active

MFDS item code 202003859 · Approved 2020.05.26 · Insurance code 646005090

Summary

Main use
Treatment of hypertension and heart failure, improvement of dyslipidemia, prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
This medicine should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, valsartan and rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is coadministered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, the dose may be increased, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose, administered twice daily. Dose reduction should be considered if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, these medicines may be switched to this medicine (a combination product with the same amounts of each active ingredient) for convenience.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Medica Korea Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of dyslipidemia, prevention of cardiovascular disease

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
View approved original text

This drug is used for patients who need to take both Valsartan and Rosuvastatin simultaneously. Valsartan helps reduce the risk of essential hypertension, heart failure, and mortality after myocardial infarction. It is especially useful for heart failure patients who are intolerant to ACE inhibitors. Rosuvastatin is used for dyslipidemias such as hypercholesterolemia, combined hyperlipidemia, and dysbetalipoproteinemia, and is administered as an adjunct when dietary control is not sufficient. It also helps lower the risk of cardiovascular diseases and stroke, myocardial infarction, and vascular reconstructive surgery. Therefore, this drug is used to improve blood pressure and blood lipid levels, enhancing cardiovascular health.

How to take

Adult dose

This medicine should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, valsartan and rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is coadministered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, the dose may be increased, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose, administered twice daily. Dose reduction should be considered if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, these medicines may be switched to this medicine (a combination product with the same amounts of each active ingredient) for convenience.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This drug can cause serious harm to the fetus when used during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Women of childbearing potential should ensure appropriate contraception before taking this drug, and it must not be used during pregnancy. Patients with severe liver or kidney dysfunction, a history of angioedema, or myopathy cannot take this drug. Elderly patients or those with high serum potassium levels or liver impairment should take this drug with special caution and may require regular monitoring. This drug may cause muscular side effects such as myalgia, myopathy, and, rarely, rhabdomyolysis, so if muscle pain or weakness occurs, medical personnel must be informed immediately. Symptoms such as abnormal liver function, dyspepsia, headache, dizziness, and nausea may occur, and if severe symptoms arise, usage should cease and a doctor should be consulted. Interactions may occur when taken with other medications, so if other drugs are being taken, they must be disclosed, especially when used with potassium-sparing diuretics, certain antibiotics, or fibrate class medications. This drug is not recommended for breastfeeding women; during breastfeeding, either the drug should be avoided, or breastfeeding should be stopped. In case of overdose, contact medical personnel immediately and receive needed treatment, as there is no specific antidote and symptom-based treatment is important. Safety for children and adolescents has not been established, and it is advisable not to administer to those under 18 years of age. Patients are advised to regularly monitor blood pressure, liver function, kidney function, and blood tests during treatment. Keep this drug in a place inaccessible to children and avoid transferring it to another container.

Side effects

Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver amino transferase (AST, ALT) levels, increased serum creatine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal rigidity, limb pain, sensory loss, anxiety, upper respiratory infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral bleeding, vomiting, insulin-dependent diabetes mellitus, diabetes complications, leg fracture, spinal fracture, fracture, skin neoplasm, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unspecified skin tumor-like conditions, shingles, intervertebral disc herniation, hemoptysis, sputum disease, bronchitis, sensory abnormalities, hoarseness, gastroesophageal reflux, diverticulitis, stomatitis, gastritis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, increased blood pressure, exacerbation of hypertension, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified dermatitis, local skin reactions, palpitations, exacerbation of angina, auditory disturbances, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, lacerations, anemia, tinnitus, tension enhancement, reduced motor function, stupor, rash, myalgia, headache, dizziness, constipation, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated drug reaction syndrome (DRESS), lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnesic syndrome, memory impairment, confusion, severe muscle weakness, ocular myasthenia, hypotension, decreased consciousness, circulatory collapse, shock, tachycardia, bradycardia, orthostatic dizziness, orthostatic hypotension, renal function impairment, hyperkalemia, angioedema, reduced urine output, progressive hypernitrogenemia, acute renal failure, vascular edema, erythema, itching, serum sickness, vasculitis, interstitial pneumonia, hypoglycemia, shock, syncope, loss of consciousness, agranulocytosis, leukopenia, thrombocytopenia, decreased red blood cell volume, decreased hemoglobin

Not everyone experiences these, and they can vary from person to person.

Storage

This drug may be sensitive to light, so it should be stored in a tightly sealed container that blocks light. Additionally, it is recommended to store the drug at room temperature between 1 degree and 30 degrees Celsius. Storing it this way will help ensure the effectiveness of the drug.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP) * 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.